Coston McIsaac & Partners Raises Holdings in CVS Health Co. (NYSE:CVS)

Coston McIsaac & Partners boosted its stake in shares of CVS Health Co. (NYSE:CVS) by 34.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 724 shares of the pharmacy operator’s stock after buying an additional 185 shares during the period. Coston McIsaac & Partners’ holdings in CVS Health were worth $57,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. SOA Wealth Advisors LLC. raised its holdings in CVS Health by 4.9% in the fourth quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after purchasing an additional 133 shares in the last quarter. Apella Capital LLC raised its stake in shares of CVS Health by 4.2% during the 4th quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock worth $272,000 after acquiring an additional 136 shares in the last quarter. Prairie Sky Financial Group LLC lifted its position in CVS Health by 4.1% during the fourth quarter. Prairie Sky Financial Group LLC now owns 3,612 shares of the pharmacy operator’s stock valued at $285,000 after acquiring an additional 141 shares during the last quarter. WealthShield Partners LLC lifted its position in CVS Health by 3.2% during the fourth quarter. WealthShield Partners LLC now owns 4,498 shares of the pharmacy operator’s stock valued at $355,000 after acquiring an additional 141 shares during the last quarter. Finally, Sugarloaf Wealth Management LLC lifted its position in CVS Health by 9.5% during the fourth quarter. Sugarloaf Wealth Management LLC now owns 1,639 shares of the pharmacy operator’s stock valued at $129,000 after acquiring an additional 142 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on CVS. SVB Leerink reissued a “market perform” rating and issued a $60.00 price objective (down previously from $87.00) on shares of CVS Health in a research report on Wednesday, May 1st. Bank of America lowered their target price on shares of CVS Health from $95.00 to $77.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. Barclays cut their price target on shares of CVS Health from $78.00 to $63.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 2nd. Robert W. Baird started coverage on shares of CVS Health in a research note on Thursday, May 30th. They set a “neutral” rating and a $61.00 price objective for the company. Finally, Piper Sandler upped their target price on CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Eleven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, CVS Health has an average rating of “Moderate Buy” and an average target price of $75.05.

Insider Activity

In other news, Director Edward J. Ludwig bought 1,000 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were acquired at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the transaction, the director now directly owns 21,630 shares in the company, valued at approximately $1,165,424.40. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.24% of the company’s stock.

CVS Health Price Performance

CVS stock traded up $0.70 during mid-day trading on Friday, reaching $59.06. 14,343,538 shares of the company’s stock were exchanged, compared to its average volume of 11,322,786. The company has a market cap of $74.14 billion, a price-to-earnings ratio of 10.38, a price-to-earnings-growth ratio of 0.56 and a beta of 0.53. The stock’s 50 day moving average is $59.56 and its 200 day moving average is $70.17. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. CVS Health Co. has a 12-month low of $52.77 and a 12-month high of $83.25.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The business had revenue of $88.44 billion for the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.20 EPS. On average, research analysts expect that CVS Health Co. will post 7.02 EPS for the current year.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.